Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Antonio Russo; Antonio Galvano; Francesco Passiglia; Francesco Pantano; Tindara Franchina; Olga Venditti; Fausto Petrelli; Enrico Vasile; Andrea Napolitano; Silvia Quadrini; Salvatore Intagliata; Daniela Iacono; Marco Imperatori; Lorenzo Calvetti; Elisa Roca; Marco Russano; Daniela Iacono; Alessandro Russo; Iacopo Fioroni; Giulia Pasquini; Michele Aieta; Mario A. Occhipinti; Luana Calabrò; Alessio Cortellini; Alfredo Berruti; Olga Martelli; Giuseppe Aprile; Maria R. Migliorino; Corrado Ficorella; Bruno Vincenzi; Vincenzo Adamo; Giovanni Mansueto; Alfredo Falcone; Alfredo Berruti; Michele Maio; Giuseppe Tonini; Sandro Barni; Daniele Santini; Anna M. Di Giacomo; Alain Gelibter; Antonio Venditti; Elena Procaccianti

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Antonio Russo, Antonio Galvano, Francesco Passiglia, Francesco Pantano, Tindara Franchina, Olga Venditti, Fausto Petrelli, Enrico Vasile, Andrea Napolitano, Silvia Quadrini, Salvatore Intagliata, Daniela Iacono, Marco Imperatori, Lorenzo Calvetti, Elisa Roca, Marco Russano, Daniela Iacono, Alessandro Russo, Iacopo Fioroni, Giulia PasquiniMichele Aieta, Mario A. Occhipinti, Luana Calabrò, Alessio Cortellini, Alfredo Berruti, Olga Martelli, Giuseppe Aprile, Maria R. Migliorino, Corrado Ficorella, Bruno Vincenzi, Vincenzo Adamo, Giovanni Mansueto, Alfredo Falcone, Alfredo Berruti, Michele Maio, Giuseppe Tonini, Sandro Barni, Daniele Santini, Anna M. Di Giacomo, Alain Gelibter, Antonio Venditti, Elena Procaccianti

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Article › peer review

1 Citazioni (Scopus)

Abstract

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

Lingua originale	English
pagine (da-a)	319-326
Numero di pagine	8
Rivista	Expert Opinion on Biological Therapy
Volume	20
Stato di pubblicazione	Published - 2020

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery
Clinical Biochemistry

Altri file e collegamenti

OA Link

Fingerprint Entra nei temi di ricerca di 'Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab'. Insieme formano una fingerprint unica.

Cita questo

Russo, A., Galvano, A., Passiglia, F., Pantano, F., Franchina, T., Venditti, O., Petrelli, F., Vasile, E., Napolitano, A., Quadrini, S., Intagliata, S., Iacono, D., Imperatori, M., Calvetti, L., Roca, E., Russano, M., Iacono, D., Russo, A., Fioroni, I., ... Procaccianti, E. (2020). Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opinion on Biological Therapy, 20, 319-326.

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. / Russo, Antonio ; Galvano, Antonio ; Passiglia, Francesco; Pantano, Francesco; Franchina, Tindara; Venditti, Olga; Petrelli, Fausto; Vasile, Enrico; Napolitano, Andrea; Quadrini, Silvia; Intagliata, Salvatore; Iacono, Daniela; Imperatori, Marco; Calvetti, Lorenzo; Roca, Elisa; Russano, Marco; Iacono, Daniela; Russo, Alessandro; Fioroni, Iacopo; Pasquini, Giulia; Aieta, Michele; Occhipinti, Mario A.; Calabrò, Luana; Cortellini, Alessio; Berruti, Alfredo; Martelli, Olga; Aprile, Giuseppe; Migliorino, Maria R.; Ficorella, Corrado; Vincenzi, Bruno; Adamo, Vincenzo; Mansueto, Giovanni; Falcone, Alfredo; Berruti, Alfredo; Maio, Michele; Tonini, Giuseppe; Barni, Sandro; Santini, Daniele; Di Giacomo, Anna M.; Gelibter, Alain; Venditti, Antonio; Procaccianti, Elena.

In: Expert Opinion on Biological Therapy, Vol. 20, 2020, pag. 319-326.

Risultato della ricerca: Article › peer review

Russo, A , Galvano, A , Passiglia, F, Pantano, F, Franchina, T, Venditti, O, Petrelli, F, Vasile, E, Napolitano, A, Quadrini, S, Intagliata, S, Iacono, D, Imperatori, M, Calvetti, L, Roca, E, Russano, M, Iacono, D, Russo, A, Fioroni, I, Pasquini, G, Aieta, M, Occhipinti, MA, Calabrò, L, Cortellini, A, Berruti, A, Martelli, O, Aprile, G, Migliorino, MR, Ficorella, C, Vincenzi, B, Adamo, V, Mansueto, G, Falcone, A, Berruti, A, Maio, M, Tonini, G, Barni, S, Santini, D, Di Giacomo, AM, Gelibter, A, Venditti, A & Procaccianti, E 2020, 'Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab', Expert Opinion on Biological Therapy, vol. 20, pagg. 319-326.

Russo, Antonio ; Galvano, Antonio ; Passiglia, Francesco ; Pantano, Francesco ; Franchina, Tindara ; Venditti, Olga ; Petrelli, Fausto ; Vasile, Enrico ; Napolitano, Andrea ; Quadrini, Silvia ; Intagliata, Salvatore ; Iacono, Daniela ; Imperatori, Marco ; Calvetti, Lorenzo ; Roca, Elisa ; Russano, Marco ; Iacono, Daniela ; Russo, Alessandro ; Fioroni, Iacopo ; Pasquini, Giulia ; Aieta, Michele ; Occhipinti, Mario A. ; Calabrò, Luana ; Cortellini, Alessio ; Berruti, Alfredo ; Martelli, Olga ; Aprile, Giuseppe ; Migliorino, Maria R. ; Ficorella, Corrado ; Vincenzi, Bruno ; Adamo, Vincenzo ; Mansueto, Giovanni ; Falcone, Alfredo ; Berruti, Alfredo ; Maio, Michele ; Tonini, Giuseppe ; Barni, Sandro ; Santini, Daniele ; Di Giacomo, Anna M. ; Gelibter, Alain ; Venditti, Antonio ; Procaccianti, Elena. / Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. In: Expert Opinion on Biological Therapy. 2020 ; Vol. 20. pagg. 319-326.

@article{4381e426d3b6433c9ed1e130541f3cbb,

title = "Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab",

abstract = "Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.",

author = "Antonio Russo and Antonio Galvano and Francesco Passiglia and Francesco Pantano and Tindara Franchina and Olga Venditti and Fausto Petrelli and Enrico Vasile and Andrea Napolitano and Silvia Quadrini and Salvatore Intagliata and Daniela Iacono and Marco Imperatori and Lorenzo Calvetti and Elisa Roca and Marco Russano and Daniela Iacono and Alessandro Russo and Iacopo Fioroni and Giulia Pasquini and Michele Aieta and Occhipinti, {Mario A.} and Luana Calabr{\`o} and Alessio Cortellini and Alfredo Berruti and Olga Martelli and Giuseppe Aprile and Migliorino, {Maria R.} and Corrado Ficorella and Bruno Vincenzi and Vincenzo Adamo and Giovanni Mansueto and Alfredo Falcone and Alfredo Berruti and Michele Maio and Giuseppe Tonini and Sandro Barni and Daniele Santini and {Di Giacomo}, {Anna M.} and Alain Gelibter and Antonio Venditti and Elena Procaccianti",

year = "2020",

language = "English",

volume = "20",

pages = "319--326",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

AU - Russo, Antonio

AU - Galvano, Antonio

AU - Passiglia, Francesco

AU - Pantano, Francesco

AU - Franchina, Tindara

AU - Venditti, Olga

AU - Petrelli, Fausto

AU - Vasile, Enrico

AU - Napolitano, Andrea

AU - Quadrini, Silvia

AU - Intagliata, Salvatore

AU - Iacono, Daniela

AU - Imperatori, Marco

AU - Calvetti, Lorenzo

AU - Roca, Elisa

AU - Russano, Marco

AU - Iacono, Daniela

AU - Russo, Alessandro

AU - Fioroni, Iacopo

AU - Pasquini, Giulia

AU - Aieta, Michele

AU - Occhipinti, Mario A.

AU - Calabrò, Luana

AU - Cortellini, Alessio

AU - Berruti, Alfredo

AU - Martelli, Olga

AU - Aprile, Giuseppe

AU - Migliorino, Maria R.

AU - Ficorella, Corrado

AU - Vincenzi, Bruno

AU - Adamo, Vincenzo

AU - Mansueto, Giovanni

AU - Falcone, Alfredo

AU - Berruti, Alfredo

AU - Maio, Michele

AU - Tonini, Giuseppe

AU - Barni, Sandro

AU - Santini, Daniele

AU - Di Giacomo, Anna M.

AU - Gelibter, Alain

AU - Venditti, Antonio

AU - Procaccianti, Elena

PY - 2020

Y1 - 2020

N2 - Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

AB - Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

UR - http://hdl.handle.net/10447/407127

M3 - Article

VL - 20

SP - 319

EP - 326

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -